Publications by authors named "Kye Hun Kim"

Background: C-acetate positron emission tomography (PET) enables simultaneous quantification of myocardial blood flow (MBF) and oxidative metabolism; however, sex-specific normative data under vasodilator stress remain insufficiently defined. We aimed to characterize these parameters in healthy individuals.

Results: Eighteen healthy individuals (9 males and 9 females, age/sex-matched; median age 43 years [range 34-65]) with normal echocardiography and no underlying cardiovascular disease underwent one-day rest-stress dynamic C-acetate PET with adenosine.

View Article and Find Full Text PDF

Background And Objectives: In chronic heart failure (HF), natriuretic peptide (NP) levels are higher in atrial fibrillation (AF) compared to sinus rhythm (SR). However, due to the loss of atrial contraction, AF patients are prone to hemodynamic decompensation at earlier stages. Since NP levels reflect disease severity, acutely decompensated AF patients may exhibit lower NP levels compared to SR patients, who retain greater hemodynamic reserve.

View Article and Find Full Text PDF

Background And Objectives: Mavacamten has shown promise in obstructive hypertrophic cardiomyopathy (oHCM); however, real-world evidence is limited in Asians. We aimed to provide the first multicenter, real-world analysis of mavacamten use in Korea.

Methods: This prospective observational study included symptomatic oHCM patients treated at 7 tertiary hospitals in Korea.

View Article and Find Full Text PDF

Purpose: This study aimed to evaluate the efficacy and safety of triple combination of ezetimibe (Eze)/atorvastatin (Ato) 10/40 mg + amlodipine (Aml) 10 mg therapy for lowering the low-density lipoprotein cholesterol (LDL-C) and blood pressure compared with either Eze/Ato 10/40 mg or Aml 10 mg therapies in patients with comorbid primary hypercholesterolemia and essential hypertension.

Methods: This was a randomized, multicenter, double-blind, active-controlled, Phase III clinical trial. Participants underwent a wash-out period (2 weeks for nonfibrate medications, 6 weeks for fibrates) followed by 4 weeks of therapeutic lifestyle changes.

View Article and Find Full Text PDF

Heart failure (HF) is a major cause of mortality and morbidity in South Korea, imposing substantial physical, emotional, and financial burdens on patients and society. Despite the high burden of symptom and complex care needs of HF patients, palliative care and hospice services remain underutilized in South Korea due to cultural, institutional, and knowledge-related barriers. This position statement from the Korean Society of Heart Failure emphasizes the need for integrating palliative and hospice care into HF management to improve quality of life and support holistic care for patients and their families.

View Article and Find Full Text PDF
Article Synopsis
  • - This study examined the diagnosis and treatment of valvular heart disease (VHD) in Korea, focusing on adult patients with moderate to severe cases through echocardiography in 45 hospitals.
  • - Out of 4,094 patients, about 1,482 had severe VHD, with varied rates of intervention depending on the type of valve issue, highlighting significant in-hospital mortality, especially for secondary severe mitral regurgitation (9.0%).
  • - The findings reveal a 5.4% overall in-hospital mortality rate, with lower mortality in patients who underwent surgical or transcatheter interventions compared to those receiving conservative treatment, suggesting the need for improved VHD management strategies in the future.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the long-term outcomes for cancer patients with improved heart function who discontinue cardioprotective therapy (CPT) after experiencing cancer treatment-related cardiac dysfunction (CTRCD).
  • Out of 134 patients analyzed, those who withdrew from CPT showed a significant decline in heart function (LVEF) compared to those who continued the therapy, especially in patients with initially low LVEF (<45%).
  • Overall, withdrawing from CPT was associated with a higher rate of major clinical events, indicating that continuing therapy may be beneficial for patients with improved CTRCD.
View Article and Find Full Text PDF

Dyadic conditions of patients with heart failure and their caregivers may affect both patient self-care and caregiver contribution to patient self-care (CCPS). The purpose of this study was to examine the relationships of patient-caregiver physical function and depressive symptoms to the patient self-care (maintenance and management) and CCPS. Data from 55 were analyzed using an Actor-Partner Interdependence Model to address the aim through AMOS.

View Article and Find Full Text PDF
Article Synopsis
  • The study explored whether evogliptin, a dipeptidyl peptidase-4 inhibitor, could slow the progression of aortic stenosis (AS) in 228 patients over 96 weeks, measuring changes in aortic valve calcium volume (AVCV).
  • Results showed no significant reduction in AVCV for either dosage of evogliptin compared to placebo; however, evogliptin groups had significantly lower active calcification volume at 48 weeks using F-sodium fluoride PET.
  • Although evogliptin did not appear to protect against AV calcification, the study suggests the potential for longer-term benefits, indicating a need for larger trials to confirm these findings.
View Article and Find Full Text PDF
Article Synopsis
  • Cachexia and sarcopenia are prevalent in heart failure patients, negatively affecting their survival, prompting this study to explore how serum creatinine levels relate to mortality in acute heart failure patients.
  • The study included 5,198 acute heart failure patients, categorized by serum creatinine levels into five groups, with a focus on post-discharge all-cause mortality and finding a J-shaped relationship between creatinine levels and mortality rates.
  • Results revealed that both low (<0.6 mg/dL) and high creatinine levels increased mortality risk, with low levels raising the risk of all-cause mortality by 33% after accounting for various health factors.
View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the incidence and outcomes of COVID-19 vaccine-related pericarditis (VRP) in a large group of vaccinated Koreans from February to December 2021.
  • Out of over 44 million vaccinated individuals, 179 cases of VRP were confirmed, with a higher incidence in males, those under 40, and recipients of mRNA vaccines.
  • The condition was rare and had good outcomes, with no fatalities, though 5.6% of cases required drainage for significant pericardial effusion, indicating the need for monitoring.
View Article and Find Full Text PDF
Article Synopsis
  • The Korean Society of Echocardiography outlines its official stance on valvular heart diseases, emphasizing clinical management.
  • The paper references recent guidelines from major cardiac organizations, including the American College of Cardiology and the European Society of Cardiology.
  • Part I of the article specifically focuses on aortic valve disease and its current situation in Korea, incorporating new research findings and Korean data.
View Article and Find Full Text PDF
Article Synopsis
  • This manuscript outlines the official stance of the Korean Society of Echocardiography on valvular heart diseases, focusing on their diagnosis and management.
  • It references recent guidelines from major cardiac organizations like the American College of Cardiology and the European Society of Cardiology.
  • The paper includes a systematic review of national data and plans to provide specific recommendations for mitral and tricuspid valve disease in a subsequent section.
View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effectiveness and tolerability of combining irbesartan (IRB) and amlodipine (AML) in treating essential hypertension when IRB alone was insufficient.
  • Two phase III clinical trials in Korea involved 428 patients and compared combinations of IRB/AML to placebo over 8 weeks, focusing on changes in mean sitting systolic blood pressure (MSSBP).
  • Results showed significant reductions in MSSBP in the combination groups compared to monotherapy, with adverse events occurring in a small percentage of participants, indicating the combined therapy was both effective and tolerable.
View Article and Find Full Text PDF

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has led to a global health crisis with substantial mortality and morbidity. To combat the COVID-19 pandemic, various vaccines have been developed, but unexpected serious adverse events including vaccine-induced thrombotic thrombocytopenia, carditis, and thromboembolic events have been reported and became a huddle for COVID-19 vaccination. Vaccine-related myocarditis (VRM) is a rare but significant adverse event associated primarily with mRNA vaccines.

View Article and Find Full Text PDF

Background: Frailty frequently coexists with hypertension in older patients. We aimed to evaluate the association between frailty and positional change in blood pressure, especially orthostatic hypertension.

Methods: Participants were recruited from 12 University hospitals in South Korea.

View Article and Find Full Text PDF

Background: As the prevalence of hypertension increases with age and the proportion of the older population is also on the rise, research on the characteristics of older hypertensive patients and the importance of frailty is necessary. This study aimed to identify clinical characteristics of older hypertension in Korea and to investigate these characteristics based on frailty status.

Methods: The HOW to Optimize eLDerly systolic BP (HOWOLD-BP) is a prospective, multicenter, open-label, randomized clinical trial that aims to compare intensive (target systolic blood pressure [SBP] ≤ 130 mmHg) with standard (target SBP ≤ 140 mmHg) treatment to reduce cardiovascular events in older hypertensive Korean patients aged ≥ 65 years.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the eligibility of heart failure patients for dapagliflozin and its cost-effectiveness compared to standard therapy, using data from the Korean Acute Heart Failure registry.
  • About 48.7% of the patients met eligibility criteria from previous clinical trials, with higher eligibility found in those with preserved ejection fraction.
  • Dapagliflozin was found to be cost-effective, especially for patients with a left ventricular ejection fraction of 40% or less, showing a significant benefit in quality-adjusted life years at a cost well below standard willingness-to-pay thresholds.
View Article and Find Full Text PDF

COVID-19 vaccination has played a pivotal role in coping with the COVID-19 pandemic by providing a powerful tool to curb the spread of the virus, reduce severe illness and hospitalizations, and ultimately save lives and facilitate a return to normal daily routines. As COVID-19 vaccination has become more widespread and more individuals have recovered from the infection, COVID-19 has entered an endemic disease phase. This phase is characterized by a less severe and more stable pattern of infection within certain regions, similar to the predictability of seasonal influenza.

View Article and Find Full Text PDF
Article Synopsis
  • The FDA and EMA approved empagliflozin for reducing cardiovascular mortality and heart failure hospitalization in patients with HFrEF and HFpEF, but its real-world applicability is unclear.
  • A study analyzing data from the Korean Acute Heart Failure (KorAHF) registry found that 91.4% of patients met FDA/EMA criteria, while only 44.7% met trial criteria.
  • Empagliflozin was determined to be cost-effective at $6,764 per quality-adjusted life year (QALY), particularly for HFrEF patients ($5,012 per QALY), indicating potential benefits in clinical settings in South Korea.
View Article and Find Full Text PDF

Aims: Although the hypothesis that metformin is beneficial for patients with diabetes and heart failure (HF) has been steadily raised, there is limited data on metformin use in patients with acute HF. We analyzed the association of metformin on all-cause mortality in hospitalized patients with type 2 diabetes and acute HF.

Methods: The Korean Acute Heart Failure registry prospectively enrolled patients hospitalized for acute HF from 2011 to 2014.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates whether tight blood pressure control can reduce left ventricular hypertrophy in asymptomatic patients with aortic valve disease, specifically aortic stenosis (AS) or aortic regurgitation (AR).
  • A total of 128 hypertensive patients were randomly divided into two treatment groups: one receiving intensive therapy targeting systolic BP <130 mm Hg, and the other receiving standard therapy targeting systolic BP <140 mm Hg.
  • Results showed that the intensive therapy group had a slight decrease in left ventricular mass, while the standard therapy group experienced an increase, indicating that intensive BP control may be beneficial for reducing LV hypertrophy in these patients.
View Article and Find Full Text PDF